Nuvation Bio (NUVB) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NUVB Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Nuvation Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.69 |
| 52 Week High | US$9.75 |
| 52 Week Low | US$1.54 |
| Beta | 1.51 |
| 1 Month Change | -17.72% |
| 3 Month Change | -40.18% |
| 1 Year Change | 104.80% |
| 3 Year Change | 182.53% |
| 5 Year Change | -66.71% |
| Change since IPO | -51.65% |
Recent News & Updates
Nuvation Bio Inc. (NUVB): Transitioning from Biotech Pipeline to Commercial Contender in 2026.
Nuvation Bio (NUVB) is navigating a high-stakes transition into a commercial-stage oncology firm, with its stock trading at $4.74 as of the March 4, 2026, afternoon session. The shares saw a notable 8.60% recovery today, partially reclaiming ground after a staggering 25.34% drop on March 3rd following its latest financial disclosures.Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade)
Feb 20Recent updates
Nuvation Bio Inc. (NUVB): Transitioning from Biotech Pipeline to Commercial Contender in 2026.
Nuvation Bio (NUVB) is navigating a high-stakes transition into a commercial-stage oncology firm, with its stock trading at $4.74 as of the March 4, 2026, afternoon session. The shares saw a notable 8.60% recovery today, partially reclaiming ground after a staggering 25.34% drop on March 3rd following its latest financial disclosures.Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade)
Feb 20Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
May 17
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Feb 13Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Aug 08Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07Nuvation Bio: A Potentially Transformative Acquisition
Jun 20Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Shareholder Returns
| NUVB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.6% | -1.0% | -0.6% |
| 1Y | 104.8% | 25.5% | 21.7% |
Return vs Industry: NUVB exceeded the US Pharmaceuticals industry which returned 24.2% over the past year.
Return vs Market: NUVB exceeded the US Market which returned 21.3% over the past year.
Price Volatility
| NUVB volatility | |
|---|---|
| NUVB Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NUVB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NUVB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 298 | David Hung | www.nuvationbio.com |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
Nuvation Bio Inc. Fundamentals Summary
| NUVB fundamental statistics | |
|---|---|
| Market cap | US$1.62b |
| Earnings (TTM) | -US$204.63m |
| Revenue (TTM) | US$62.90m |
Is NUVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUVB income statement (TTM) | |
|---|---|
| Revenue | US$62.90m |
| Cost of Revenue | US$9.30m |
| Gross Profit | US$53.60m |
| Other Expenses | US$258.23m |
| Earnings | -US$204.63m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 85.22% |
| Net Profit Margin | -325.31% |
| Debt/Equity Ratio | 20.4% |
How did NUVB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 09:07 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nuvation Bio Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |